Editas Medicine, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
EDIT$2.51-8.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Condensed Consolidated Balance Sheets
(amounts in thousands, except share and per share data)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $93,169 | $146,645 |
| Marketable securities | 97,029 | — |
| Accounts receivable | 7,727 | 15,176 |
| Prepaid expenses and other current assets | 4,048 | 2,074 |
| Total current assets | 201,973 | 163,895 |
| Property and equipment, net | 2,189 | 3,542 |
| Right-of-use assets | 12,274 | 16,121 |
| Restricted cash and other non-current assets | 2,976 | 2,976 |
| Total assets | $219,412 | $186,534 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $6,817 | $2,605 |
| Accrued expenses | 18,442 | 32,610 |
| Liability for sale of future revenues, current | 7,500 | 5,000 |
| Deferred revenue, current | 32,315 | — |
| Operating lease liabilities, current | 6,508 | 6,031 |
| Total current liabilities | 71,582 | 46,246 |
| Operating lease liabilities, net of current portion | 7,433 | 12,071 |
| Liability for sale of future revenues, net of current portion | 49,320 | 53,605 |
| Deferred revenue, net of current portion | 4,000 | 44,509 |
| Other non-current liabilities | 2,557 | 2,815 |
| Total liabilities | 134,892 | 159,246 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, $0.0001 par value per share: 390,000,000 shares authorized; 153,657,962 and 97,866,996 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 15 | 10 |
| Additional paid-in capital | 1,779,709 | 1,655,781 |
| Accumulated other comprehensive loss | (96) | — |
| Accumulated deficit | (1,695,108) | (1,628,503) |
| Total stockholders’ equity | 84,520 | 27,288 |
| Total liabilities and stockholders’ equity | $219,412 | $186,534 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.